Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz

NEW YORK, October 7, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), CVS Health Corporation (NYSE: CVS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Allergan Inc. (NYSE: AGN) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6968-100free.

--
Regeneron Pharmaceuticals, Inc. Research Reports
On September 30, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) and Paris-based Sanofi jointly announced that a Phase 2a proof-of-concept study of Dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. According to the Company, Dupilumab was created using Regeneron's pioneering VelocImmune® technology and is being co-developed with Sanofi in atopic dermatitis, asthma and CSwNP. Meeting the primary endpoint of the study, dupilumab resulted in a statistically-significant improvement in the size of nasal polyps, as measured by endoscopic Nasal Polyp Score (NPS), said the Company. "The new data reported today, together with prior Phase 2 data with dupilumab in asthma and atopic dermatitis, support the growing body of scientific evidence that these conditions may result from a core allergic inflammatory process driven by the IL-4/IL-13 pathway," said Neil Graham, M.D., Vice President, Program Management at Regeneron. The full research reports on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/REGN/report.pdf

--
CVS Health Corporation Research Reports
On September 24, 2014, CVS Health Corporation (CVS Health) announced that its board of directors has approved a common stock quarterly dividend of $0.275 per share, payable on November 3, 2014, to holders of record on October 23, 2014. The full research reports on CVS Health are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/CVS/report.pdf

--
Valeant Pharmaceuticals International, Inc. Research Reports
On September 30, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) announced that its Bridgewater, New Jersey location received a Warning Letter from the U.S. Food and Drug Administration (FDA). According to the Company, the FDA's warning letter relates to inspection in June 2014 of the Company's records with regards to Sculptra Aesthetic injectable, which was divested to Galderma S.A. in July 2014. The letter is regarding the management of the Company's contract manufacturers (rather than Valeant's own internal manufacturing) pertaining to some specific Good Manufacturing Practice (GMP) activities, including review and documentation of supplier's deviation reports prior to batch release and performing corrective and preventive action (CAPA) effectiveness checks as required by procedure. Valeant said that the warning letter does not prevent the manufacturing or distribution of Sculptra or any other product of the Company. Valeant also said that it will address the FDA's concerns shortly. The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/VRX/report.pdf

--
Allergan Inc. Research Reports
On September 29, 2014, Allergan Inc.'s (Allergan's) Board of Directors issued a statement to reiterate the Company's opposition to the Valeant Pharmaceuticals International, Inc.'s (Valeant) acquisition offer. Following is an excerpt from the statement: "Our conclusion that Valeant's offer is grossly inadequate and substantially undervalues Allergan remains unchanged. We continue to believe strongly that Valeant's offer does not appropriately reflect the underlying value of Allergan's assets, operations and prospects, including Allergan's industry-leading franchises of global scale and its projected growth opportunities." Valeant has been trying to acquire Allergan since April 2014 and has the support of Bill Ackman led Pershing Square Capital Management LP - one of the largest shareholders in Allergan. According to a blog on the Wall Street Journal, this Board statement has come after some more Allergan shareholders, including T. Rowe Price, Pentwater Capital Management and Jackson Square Partners, have come out in support of Valeant takeover. The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/AGN/report.pdf

--
Jazz Pharmaceuticals plc Research Reports
On September 30, 2014, the stock of Jazz Pharmaceuticals plc (Jazz) fell 0.99% to end the trading session at $160.56. During the session, shares in Jazz opened at $162.63, and moved in the range of $160.00 - $163.20, with a total of 1.49 million shares changing hands. The stock remained above its 50-day and 200-day moving averages of $154.35 and $146.01, respectively. Over the last one month, the Company's stock has declined by 1.45%, compared to the Nasdaq Composite index which fell 1.90% during that period. The stock has a 52-week high of $176.60 and a 52-week low of $80.40. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Oct-07-2014/JAZZ/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review